Sperlich Catherine, Saad Fred
Hematologist-Oncologist and Professeur d'Enseignement Clinique, Clinique Intégrée de Cancérologie de la Montérégie (CICM), CSSS Charles-Le Moyne, Greenfield Park, QC;
Can Urol Assoc J. 2013 Jan-Feb;7(1-2 Suppl 1):S18-24. doi: 10.5489/cuaj.275.
The emergence of chemotherapy as a survival-improving treatment for metastatic castration-resistant prostate cancer has focused attention on the need for effective prevention and management of side effects. The most recent chemotherapeutic agent in this setting is cabazitaxel, licensed for use when the disease progresses on or after docetaxel-based treatment. Experience with cabazitaxel shows that, as with docetaxel, its side effects are largely predictable and manageable using methods that are already well-known to oncology teams. Patient education, clear instructions for when and how patients should seek advice, and properly implemented local policies on side effect management are essential to optimal patient care.
化疗作为转移性去势抵抗性前列腺癌的一种改善生存的治疗方法的出现，使人们将注意力集中在有效预防和管理副作用的必要性上。在这种情况下，最新的化疗药物是卡巴他赛，在基于多西他赛的治疗期间或之后疾病进展时被批准使用。卡巴他赛的使用经验表明，与多西他赛一样，其副作用在很大程度上是可预测的，并且可以使用肿瘤学团队已经熟知的方法进行管理。患者教育、关于患者何时以及如何寻求建议的明确指示，以及正确实施的副作用管理地方政策对于优化患者护理至关重要。
